On October 30, 2024, Cognition conducted an investor webcast during the 2024 Clinical Trials on Alzheimer’s Disease (CTAD) conference. During this event, management presented a pre-specified analysis of data from the Phase 2 SHINE study (NCT03507790) of CT1812 in participants with mild-to-moderate Alzheimer’s disease. An archived recording of that event is available below.
Download the presentation (PDF)
Investor Webinar: Analysis of the Lower p-tau217 Subgroup from SHINE
October 30, 2024
8:00 am
ET